Nouvex™ is a patented antimicrobial technology discovered at Purdue University. Nouvex is currently being developed for commercialization by Poly Group LLC under a worldwide exclusive licensing agreement with the Purdue Research Foundation.
Nouvex is a polymeric technology that is compatible with a wide range of substrates. The addition of Nouvex antimicrobial polymer renders substrates antimicrobial. The antimicrobial nature of the Nouvex treated substrate is persistent, enabling materials to retain its antimicrobial activity for an extended time. Persistency in combination with Nouvex’s low toxicity and significant biocompatibility potentially allows Nouvex to be used in products such as wound dressings and implantable medical devices in both human and animal applications.
Poly Group, LLC has demonstrated the efficacy of Nouvex technology in numerous substrates, including textiles, coatings, paper, plastics, and powder coatings. It has significant advantages over other antimicrobials in terms of efficacy, cost, and versatility. Nouvex technology is scalable and can be customized for various applications.
Nouvex is fast-acting, less toxic, and longer-lasting than most other current antimicrobial additives. Poly Group LLC has successfully registered Nouvex with the U.S. Environmental Protection Agency (EPA), Office of Pesticide Programs, Antimicrobial Division as a material preservative; EPA Reg. No. 91413-2.
Poly Group LLC is currently seeking joint development partnerships with companies who wish to enhance their product line with this groundbreaking technology. Exclusive marketing options are also available. Such arrangements will include a variety of non-disclosure documentation, option fees, and research requirements.